{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:14:38Z","timestamp":1793873678043,"version":"4.6.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HHT has emerged as a notable compound in the realm of cancer treatment, particularly for hematological malignancies. Its multifaceted pharmacological properties extend beyond traditional applications, warranting an extensive review of its mechanisms and efficacy. This review aims to synthesize comprehensive insights into the efficacy of HHT in treating hematological malignancies, diverse cancers, and other biomedical applications. It focuses on elucidating the molecular mechanisms, therapeutic potential, and broader applications of HHT. A comprehensive search for peer-reviewed papers was conducted across various academic databases, including ScienceDirect, Web of Science, Scopus, American Chemical Society, Google Scholar, PubMed\/MedLine, and Wiley. The review highlights HHT's diverse mechanisms of action, ranging from its role in leukemia treatment to its emerging applications in managing other cancers and various biomedical conditions. It underscores HHT's influence on cellular processes, its efficacy in clinical settings, and its potential to alter pathological pathways. HHT demonstrates significant promise in treating various hematological malignancies and cancers, offering a multifaceted approach to disease management. Its ability to impact various physiological pathways opens new avenues for therapeutic applications. This review provides a consolidated foundation for future research and clinical applications of HHT in diverse medical fields.<\/jats:p>","DOI":"10.1186\/s40001-024-01856-x","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T07:01:50Z","timestamp":1714806110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications"],"prefix":"10.1186","volume":"29","author":[{"given":"Somanjana","family":"Khatua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeshna","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surjit","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arghya","family":"Naskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda S\u00f6nmez","family":"G\u00fcrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnendu","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"20","key":"1856_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"1","key":"1856_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-021-00198-2","volume":"10","author":"M Keykhaei","year":"2021","unstructured":"Keykhaei M, Masinaei M, Mohammadi E, Azadnajafabad S, Rezaei N, Saeedi Moghaddam S, Rezaei N, Nasserinejad M, Abbasi-Kangevari M, Malekpour M-R, Ghamari S-H, Haghshenas R, Koliji K, Kompani F, Farzadfar F. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990\u20132017. Exp Hematol Oncol. 2021;10(1):11. https:\/\/doi.org\/10.1186\/s40164-021-00198-2.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1856_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/2225-4110.124335","volume":"4","author":"L-T Lin","year":"2014","unstructured":"Lin L-T, Hsu W-C, Lin C-C. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014;4(1):24\u201335.","journal-title":"J Tradit Complement Med"},{"issue":"3","key":"1856_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20(3):158\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1856_CR5","doi-asserted-by":"publisher","first-page":"12070","DOI":"10.1038\/s41598-019-48445-1","volume":"9","author":"T Hao","year":"2019","unstructured":"Hao T, Li-Talley M, Buck A, Chen W. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci Rep. 2019;9(1):12070. https:\/\/doi.org\/10.1038\/s41598-019-48445-1.","journal-title":"Sci Rep"},{"key":"1856_CR6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/GO.21.00194","volume":"7","author":"Y Hu","year":"2021","unstructured":"Hu Y, Li Q, Hou M, Peng J, Yang X, Xu S. Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the global burden of disease study 2019. JCO Glob Oncol. 2021;7:1429\u201341.","journal-title":"JCO Glob Oncol"},{"issue":"4","key":"1856_CR7","first-page":"3233","volume":"20","author":"J Wu","year":"2019","unstructured":"Wu J, Wei B, Shi Y, Lu X, Ding Y, Wang C, Li Y. Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX. Mol Med Rep. 2019;20(4):3233\u20139.","journal-title":"Mol Med Rep"},{"issue":"5","key":"1856_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00280-008-0805-8","volume":"63","author":"RM Stone","year":"2009","unstructured":"Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, DeAngelo DJ, Marcucci G, Bloomfield CD, Larson RA. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009;63(5):859\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1856_CR9","doi-asserted-by":"publisher","unstructured":"Shallis RM, Wang R, Davidoff A., Ma X, & Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood reviews. 2019;36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005.","DOI":"10.1016\/j.blre.2019.04.005"},{"issue":"10","key":"1856_CR10","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1016\/j.clml.2021.06.002","volume":"21","author":"R Mi","year":"2021","unstructured":"Mi R, Zhao J, Chen L, Wei X, Liu J. Efficacy and safety of homoharringtonine for the treatment of acute myeloid leukemia: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2021;21(10):e752\u201367.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"1856_CR11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.7150\/ijbs.44907","volume":"17","author":"L-b Wang","year":"2021","unstructured":"Wang L-b, Wang D-n, Wu L-g, Cao J, Tian J-h, Liu R, Ma R, Yu J-j, Wang J, Huang Q. Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p\/AKT\/mTOR signaling pathway. Int J Biol Sci. 2021;17(4):995.","journal-title":"Int J Biol Sci"},{"issue":"23","key":"1856_CR12","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1002\/cncr.24601","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009;115(23):5382\u201393.","journal-title":"Cancer"},{"issue":"11","key":"1856_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/v10110601","volume":"10","author":"H-J Dong","year":"2018","unstructured":"Dong H-J, Wang Z-H, Meng W, Li C-C, Hu Y-X, Zhou L, Wang X-J. The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo. Viruses. 2018;10(11):601.","journal-title":"Viruses"},{"issue":"5","key":"1856_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.clml.2013.03.017","volume":"13","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes J. Homoharringtonine\/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013;13(5):530\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"1856_CR15","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.3390\/ijms19113533","volume":"19","author":"A Lichota","year":"2018","unstructured":"Lichota A, Gwozdzinski K. Anticancer activity of natural compounds from plant and marine environment. Int J Mol Sci. 2018;19(11):3533.","journal-title":"Int J Mol Sci"},{"key":"1856_CR16","doi-asserted-by":"publisher","first-page":"108774","DOI":"10.1016\/j.abb.2021.108774","volume":"700","author":"J-f Tang","year":"2021","unstructured":"Tang J-f, Li G-l, Zhang T, Du Y-m, Huang S-y, Ran J-h, Li J, Chen D-l. Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2\/M cell cycle arrest. Arch Biochem Biophys. 2021;700:108774.","journal-title":"Arch Biochem Biophys"},{"issue":"20","key":"1856_CR17","doi-asserted-by":"publisher","first-page":"10930","DOI":"10.3390\/ijms222010930","volume":"22","author":"S Guo","year":"2021","unstructured":"Guo S, Bai X, Shi S, Deng Y, Kang X, An H. TMEM16A, a homoharringtonine receptor, as a potential endogenic target for lung cancer treatment. Int J Mol Sci. 2021;22(20):10930.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1856_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-19621-7","volume":"12","author":"R Plett","year":"2022","unstructured":"Plett R, Mellor P, Kendall S, Hammond SA, Boulet A, Plaza K, Vizeacoumar FS, Vizeacoumar FJ, Anderson DH. Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel. Sci Rep. 2022;12(1):1\u201316.","journal-title":"Sci Rep"},{"issue":"3\u20134","key":"1856_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000519974","volume":"21","author":"X Jiang","year":"2021","unstructured":"Jiang X, Wu Q, Zhang C, Wang M. Homoharringtonine inhibits Alzheimer\u2019s disease progression by reducing neuroinflammation via STAT3 signaling in APP\/PS1 mice. Neurodegener Dis. 2021;21(3\u20134):93\u2013102.","journal-title":"Neurodegener Dis"},{"key":"1856_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ejphar.2017.09.027","volume":"815","author":"X Li","year":"2017","unstructured":"Li X, Wang S, Dai J, Yan L, Zhao S, Wang J, Sun Y. Homoharringtonine prevents surgery-induced epidural fibrosis through endoplasmic reticulum stress signaling pathway. Eur J Pharmacol. 2017;815:437\u201345.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1856_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-7-2","volume":"7","author":"S L\u00fc","year":"2014","unstructured":"L\u00fc S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol. 2014;7(1):1\u201310.","journal-title":"J Hematol Oncol"},{"key":"1856_CR22","unstructured":"PubChem. https:\/\/pubchem.ncbi.nlm.nih.gov\/. Accessed 16 Jan 2023."},{"key":"1856_CR23","unstructured":"WFO. 2023. https:\/\/www.worldfloraonline.org\/. Accessed 21 Jan 2023."},{"issue":"1","key":"1856_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00606-008-0069-0","volume":"276","author":"DC Hao","year":"2008","unstructured":"Hao DC, Xiao PG, Huang B, Ge GB, Yang L. Interspecific relationships and origins of Taxaceae and Cephalotaxaceae revealed by partitioned Bayesian analyses of chloroplast and nuclear DNA sequences. Plant Syst Evol. 2008;276(1):89\u2013104.","journal-title":"Plant Syst Evol"},{"issue":"4","key":"1856_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4149\/neo_2016_401","volume":"63","author":"L Novotny","year":"2016","unstructured":"Novotny L, Al-Tannak N, Hunakova L. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate). Neoplasma. 2016;63(4):495\u2013503.","journal-title":"Neoplasma"},{"key":"1856_CR26","unstructured":"Vidakovi\u0107 M. Conifers: morphology and variation. Grafi\u010dko Zavod Hrvatske. 1991."},{"issue":"1","key":"1856_CR27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5962\/p.251135","volume":"55","author":"KE Tripp","year":"1995","unstructured":"Tripp KE. Cephalotaxus: the plum yews. Arnoldia. 1995;55(1):24\u201339.","journal-title":"Arnoldia"},{"key":"1856_CR28","unstructured":"Silba J (1986) Encyclopaedia coniferae. In: Phytologia memoirs. Vol VIII. Corvallis: Moldenke and Moldenke,"},{"issue":"6","key":"1856_CR29","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","volume":"92","author":"HM Kantarjian","year":"2001","unstructured":"Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O\u2019Brien SM. Homoharringtonine: history, current research, and future directions. Cancer. 2001;92(6):1591\u2013605.","journal-title":"Cancer"},{"issue":"46","key":"1856_CR30","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1016\/S0040-4039(01)88620-2","volume":"10","author":"R Powell","year":"1969","unstructured":"Powell R, Weisleder D, Smith C Jr, Wolff I. Structure of cephalotaxine and related alkaloids. Tetrahedron Lett. 1969;10(46):4081\u20134.","journal-title":"Tetrahedron Lett"},{"issue":"11","key":"1856_CR31","first-page":"1934578X0900401","volume":"4","author":"W-J Dai","year":"2009","unstructured":"Dai W-J, Dai H-F, Wu J, Liu J, Mei W-L. A new 5-acyl-2-methylpyrrole from the endophytic fungus S20 of Cephalotaxus hainanensis. Nat Prod Commun. 2009;4(11):1934578X0900401110.","journal-title":"Nat Prod Commun"},{"issue":"3","key":"1856_CR32","first-page":"446","volume":"4","author":"P Saithong","year":"2010","unstructured":"Saithong P, Panthavee W, Stonsaovapak S, Li C. Isolation and primary identification of endophytic fungi from Cephalotaxus mannii trees. Maejo Int J Sci Technol. 2010;4(3):446\u201353.","journal-title":"Maejo Int J Sci Technol"},{"issue":"11","key":"1856_CR33","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1021\/acs.orglett.1c01323","volume":"23","author":"T Sakai","year":"2021","unstructured":"Sakai T, Okumura C, Futamura M, Noda N, Nagae A, Kitamoto C, Kamiya M, Mori Y. Gold (I)-catalyzed cyclization\u20133-aza-cope\u2013mannich cascade and its application to the synthesis of cephalotaxine. Org Lett. 2021;23(11):4391\u20135.","journal-title":"Org Lett"},{"issue":"4","key":"1856_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.fitote.2012.02.012","volume":"83","author":"X Lu","year":"2012","unstructured":"Lu X, Chen G, Hua H, Dai H, Mei W, Xu Y, Pei Y. Aromatic compounds from endophytic fungus Colletotrichum sp. L10 of Cephalotaxus hainanensis Li. Fitoterapia. 2012;83(4):737\u201341.","journal-title":"Fitoterapia"},{"issue":"1","key":"1856_CR35","first-page":"28","volume":"6","author":"H Xue","year":"2012","unstructured":"Xue H, Lu C, Liang L, Shen Y. Secondary metabolites of Aspergillus sp. CM9a, an endophytic fungus of Cephalotaxus mannii. Rec Nat Prod. 2012;6(1):28\u201334.","journal-title":"Rec Nat Prod"},{"issue":"7","key":"1856_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11274-015-1971-6","volume":"32","author":"X Hu","year":"2016","unstructured":"Hu X, Li W, Yuan M, Li C, Liu S, Jiang C, Wu Y, Cai K, Liu Y. Homoharringtonine production by endophytic fungus isolated from Cephalotaxus hainanensis Li. World J Microbiol Biotechnol. 2016;32(7):1\u20139.","journal-title":"World J Microbiol Biotechnol"},{"key":"1856_CR37","doi-asserted-by":"publisher","first-page":"719694","DOI":"10.3389\/fphar.2021.719694","volume":"12","author":"M Tilaoui","year":"2021","unstructured":"Tilaoui M, Mouse HA, Zyad A. Update and new insights on future cancer drug candidates from plant-based alkaloids. Front Pharmacol. 2021;12:719694.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1856_CR38","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s11814-009-0181-z","volume":"26","author":"B-S Kim","year":"2009","unstructured":"Kim B-S, Kim J-H. Characterization of solvent induced crystalline and amorphous homoharringtonine. Korean J Chem Eng. 2009;26(4):1090\u20133.","journal-title":"Korean J Chem Eng"},{"key":"1856_CR39","doi-asserted-by":"publisher","first-page":"112801","DOI":"10.1016\/j.jpba.2019.112801","volume":"176","author":"X Gu","year":"2019","unstructured":"Gu X, Chen Y, Lou Y, Zheng J. Separation and characterization of forced degradation products in homoharringtonine injection by UHPLC-Q-TOF-MS. J Pharm Biomed Anal. 2019;176:112801.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"1856_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/chromsci\/41.2.67","volume":"41","author":"YH Choi","year":"2003","unstructured":"Choi YH, Yoo K-P, Kim J. HPLC-electrospray ionization-MS-MS analysis of Cephalotaxus harringtonia leaves and enhancement of the extraction efficiency of alkaloids therein by SFE. J Chromatogr Sci. 2003;41(2):67\u201372.","journal-title":"J Chromatogr Sci"},{"issue":"12","key":"1856_CR41","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1002\/aic.16413","volume":"64","author":"RS Nett","year":"2018","unstructured":"Nett RS, Guan X, Smith K, Faust AM, Sattely ES, Fischer CR. D2O labeling to measure active biosynthesis of natural products in medicinal plants. AIChE J. 2018;64(12):4319\u201330.","journal-title":"AIChE J"},{"issue":"3","key":"1856_CR42","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1021\/ja00523a029","volume":"102","author":"RJ Parry","year":"1980","unstructured":"Parry RJ, Chang MN, Schwab JM, Foxman B. Biosynthesis of the Cephalotaxus alkaloids: investigations of the early and late stages of cephalotaxine biosynthesis. J Am Chem Soc. 1980;102(3):1099\u2013111.","journal-title":"J Am Chem Soc"},{"issue":"24","key":"1856_CR43","doi-asserted-by":"publisher","first-page":"8629","DOI":"10.1021\/ja00779a082","volume":"94","author":"M Semmelhack","year":"1972","unstructured":"Semmelhack M, Chong B, Jones L. Total synthesis of Cephalotaxus alkaloids. J Am Chem Soc. 1972;94(24):8629\u201330.","journal-title":"J Am Chem Soc"},{"issue":"9","key":"1856_CR44","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1021\/ja00842a030","volume":"97","author":"SM Weinreb","year":"1975","unstructured":"Weinreb SM, Auerbach J. Total synthesis of the Cephalotaxus alkaloids: cephalotaxine, cephalotaxinone, and demethylcephalotaxinone. J Am Chem Soc. 1975;97(9):2503\u20136.","journal-title":"J Am Chem Soc"},{"issue":"9","key":"1856_CR45","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1021\/acs.orglett.6b00659","volume":"18","author":"P Gouthami","year":"2016","unstructured":"Gouthami P, Chegondi R, Chandrasekhar S. Formal total synthesis of (\u00b1)-cephalotaxine and congeners via aryne insertion reaction. Org Lett. 2016;18(9):2044\u20136.","journal-title":"Org Lett"},{"issue":"20","key":"1856_CR46","doi-asserted-by":"publisher","first-page":"6824","DOI":"10.1002\/ange.201902174","volume":"131","author":"X Ju","year":"2019","unstructured":"Ju X, Beaudry CM. Total synthesis of (\u2212)-cephalotaxine and (\u2212)-homoharringtonine via furan oxidation-transannular mannich cyclization. Angew Chem. 2019;131(20):6824\u20137.","journal-title":"Angew Chem"},{"issue":"2","key":"1856_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/00397911.2020.1829643","volume":"51","author":"F-F Dang","year":"2021","unstructured":"Dang F-F, Wang C-C, Han F, Zhang Z-W. Synthesis of the ester side chains of homoharringtonine and harringtonine using lactones as building blocks. Synth Commun. 2021;51(2):317\u201323.","journal-title":"Synth Commun"},{"issue":"34","key":"1856_CR48","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1016\/S0040-4039(00)87634-0","volume":"23","author":"S Hiranuma","year":"1982","unstructured":"Hiranuma S, Hudlicky T. Synthesis of homoharringtonine and its derivative by partial esterification of cephalotaxine. Tetrahedron Lett. 1982;23(34):3431\u20134.","journal-title":"Tetrahedron Lett"},{"issue":"14","key":"1856_CR49","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1021\/ol8010166","volume":"10","author":"WR Esmieu","year":"2008","unstructured":"Esmieu WR, Worden SM, Catterick D, Wilson C, Hayes CJ. A formal synthesis of (-)-cephalotaxine. Org Lett. 2008;10(14):3045\u20138.","journal-title":"Org Lett"},{"issue":"12","key":"1856_CR50","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.1021\/acs.joc.9b00933","volume":"84","author":"H Jeon","year":"2019","unstructured":"Jeon H, Chung Y, Kim S. Proline ester enolate claisen rearrangement and formal total synthesis of (\u2212)-cephalotaxine. J Org Chem. 2019;84(12):8080\u20139.","journal-title":"J Org Chem"},{"key":"1856_CR51","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71880","volume":"11","author":"C Yang","year":"2022","unstructured":"Yang C, Zhang H, Chen M, Wang S, Qian R, Zhang L, Huang X, Wang J, Liu Z, Qin W. A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. Elife. 2022;11: e71880.","journal-title":"Elife"},{"issue":"3","key":"1856_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.bjc.6603265","volume":"95","author":"V Levy","year":"2006","unstructured":"Levy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer. 2006;95(3):253\u20139.","journal-title":"Br J Cancer"},{"key":"1856_CR53","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.phytol.2013.11.010","volume":"7","author":"J Khazir","year":"2014","unstructured":"Khazir J, Mir BA, Pilcher L, Riley DL. Role of plants in anticancer drug discovery. Phytochem Lett. 2014;7:173\u201381.","journal-title":"Phytochem Lett"},{"issue":"3","key":"1856_CR54","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1517\/17460441.2.3.361","volume":"2","author":"N Darwiche","year":"2007","unstructured":"Darwiche N, El-Banna S, Gali-Muhtasib H. Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development. Expert Opin Drug Discov. 2007;2(3):361\u201379.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"1856_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/138161211795049778","volume":"17","author":"M Wetzler","year":"2011","unstructured":"Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des. 2011;17(1):59\u201364.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1856_CR56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bph.13359","volume":"173","author":"T Zhang","year":"2016","unstructured":"Zhang T, Shen S, Zhu Z, Lu S, Yin X, Zheng J, Jin J. Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia. Br J Pharmacol. 2016;173(1):212\u201321.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1856_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4103\/jpp.jpp_52_21","volume":"12","author":"A Muralidharan","year":"2021","unstructured":"Muralidharan A, Scott JJX, Joseph LD, Jeyabalan S. Effect of homoharringtonine as a combined regimen for acute myeloid leukemia. J Pharmacol Pharmacother. 2021;12(3):110\u20134.","journal-title":"J Pharmacol Pharmacother"},{"key":"1856_CR58","doi-asserted-by":"publisher","first-page":"931527","DOI":"10.3389\/fonc.2022.931527","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li N, Chang Z, Wang H, Pei H, Zhang D, Zhang Q, Huang J, Guo Y, Zhao Y. The metabolic signature of AML cells treated with homoharringtonine. Front Oncol. 2022;12:931527.","journal-title":"Front Oncol"},{"issue":"2","key":"1856_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019001239","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85\u201396.","journal-title":"Blood"},{"key":"1856_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/104631","author":"H Reikvam","year":"2011","unstructured":"Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud \u00d8. Acute myeloid leukemia with the t (8; 21) translocation: clinical consequences and biological implications. J Biomed Biotechnol. 2011. https:\/\/doi.org\/10.1155\/2011\/104631.","journal-title":"J Biomed Biotechnol"},{"issue":"3","key":"1856_CR61","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11684-018-0624-1","volume":"13","author":"W Zhang","year":"2019","unstructured":"Zhang W, Lu Y, Zhen T, Chen X, Zhang M, Liu P, Weng X, Chen B, Wang Y. Homoharringtonine synergy with oridonin in treatment of t (8; 21) acute myeloid leukemia. Front Med. 2019;13(3):388\u201397.","journal-title":"Front Med"},{"issue":"1","key":"1856_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0774-x","volume":"12","author":"C Lai","year":"2019","unstructured":"Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol. 2019;12(1):1\u201320.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1856_CR63","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/cancers11121827","volume":"11","author":"D Watanabe","year":"2019","unstructured":"Watanabe D, Nogami A, Okada K, Akiyama H, Umezawa Y, Miura O. FLT3-ITD activates RSK1 to enhance proliferation and survival of AML cells by activating mTORC1 and eIF4B cooperatively with PIM or PI3K and by inhibiting bad and BIM. Cancers. 2019;11(12):1827.","journal-title":"Cancers"},{"issue":"4","key":"1856_CR64","first-page":"488","volume":"128","author":"Y Ofran","year":"2016","unstructured":"Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood J Am Soc Hematol. 2016;128(4):488\u201396.","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"1856_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):1\u201325.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1856_CR66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2019.234880","volume":"105","author":"SK Bohlander","year":"2020","unstructured":"Bohlander SK. A new kid on the block for acute myeloid leukemia treatment? Homoharringtonine interferes with key pathways in acute myeloid leukemia cells. Haematologica. 2020;105(1):7.","journal-title":"Haematologica"},{"issue":"7","key":"1856_CR67","first-page":"2031","volume":"50","author":"J-Y Zhou","year":"1990","unstructured":"Zhou J-Y, Chen D-L, Shen Z-S, Koeffler HP. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Can Res. 1990;50(7):2031\u20135.","journal-title":"Can Res"},{"issue":"21","key":"1856_CR68","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1182\/blood.V122.21.5006.5006","volume":"122","author":"J He","year":"2013","unstructured":"He J, Li L, Zhu J, Zhao Y, Wu W, Zheng Y, Zheng G, Zheng W, Zhu X, Huang H. Homoharringtonine in combination with cytarabine and etoposide for induction therapy in patients with de novo acute myelogenous leukemia. Blood. 2013;122(21):5006.","journal-title":"Blood"},{"issue":"3","key":"1856_CR69","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","volume":"5","author":"R Tang","year":"2006","unstructured":"Tang R, Faussat A-M, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O, Marie J-P. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5(3):723\u201331.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1856_CR70","doi-asserted-by":"publisher","first-page":"490","DOI":"10.21037\/atm-22-1459","volume":"10","author":"F Yuan","year":"2022","unstructured":"Yuan F, Li D, Li G, Cheng C, Wei X. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms. Ann Transl Med. 2022;10(8):490.","journal-title":"Ann Transl Med"},{"issue":"10","key":"1856_CR71","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.leukres.2013.06.023","volume":"37","author":"L Wang","year":"2013","unstructured":"Wang L, You L-S, Ni W-M, Ma Q-L, Tong Y, Mao L-P, Qian J-J, Jin J. \u03b2-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res. 2013;37(10):1329\u201340.","journal-title":"Leuk Res"},{"issue":"11","key":"1856_CR72","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1002\/cam4.913","volume":"5","author":"J Cao","year":"2016","unstructured":"Cao J, Feng H, Ding NN, Qy Wu, Chen C, Niu MS, Chen W, Qiu TT, Zhu HH, Xu KL. Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t (8; 21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein. Cancer Med. 2016;5(11):3205\u201313.","journal-title":"Cancer Med"},{"key":"1856_CR73","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2147\/CMAR.S187597","volume":"11","author":"J Zhang","year":"2019","unstructured":"Zhang J, Geng H, Liu L, Zhang H. Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense. Cancer Manag Res. 2019;11:1023.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"1856_CR74","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.tranon.2019.02.016","volume":"12","author":"Z Wu","year":"2019","unstructured":"Wu Z, Zhuang H, Yu Q, Zhang X, Jiang X, Lu X, Xu Y, Yang L, Wu B, Ma A. Homoharringtonine combined with the heat shock protein 90 inhibitor IPI504 in the treatment of FLT3-ITD acute myeloid leukemia. Transl Oncol. 2019;12(6):801\u20139.","journal-title":"Transl Oncol"},{"issue":"8","key":"1856_CR75","doi-asserted-by":"publisher","first-page":"12764","DOI":"10.18632\/oncotarget.14463","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, Yin X, Wang H, Huang J, Yu M, Ma Z, Li C, Zhou Y, Yan X, Huang S. The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia. Oncotarget. 2017;8(8):12764.","journal-title":"Oncotarget"},{"key":"1856_CR76","doi-asserted-by":"publisher","first-page":"114538","DOI":"10.1016\/j.bcp.2021.114538","volume":"188","author":"F Wang","year":"2021","unstructured":"Wang F, Huang J, Guo T, Zheng Y, Zhang L, Zhang D, Wang F, Naren D, Cui Y, Liu X. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway. Biochem Pharmacol. 2021;188:114538.","journal-title":"Biochem Pharmacol"},{"key":"1856_CR77","doi-asserted-by":"publisher","first-page":"692497","DOI":"10.3389\/fonc.2021.692497","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Ye J, Yang Y, Zhao Y, Shen H, Ye X, Xie W. The basic research of the combinatorial therapy of ABT-199 and homoharringtonine on acute myeloid leukemia. Front Oncol. 2021;11:692497. https:\/\/doi.org\/10.3389\/fonc.2021.692497.","journal-title":"Front Oncol"},{"issue":"5","key":"1856_CR78","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","volume":"22","author":"M Klanova","year":"2016","unstructured":"Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman K. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2-and MCL1-dependent subgroups of diffuse large B-cell lymphoma targeting of BCL2 proteins in diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22(5):1138\u201349.","journal-title":"Clin Cancer Res"},{"key":"1856_CR79","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-138676","volume":"136","author":"G Yu","year":"2020","unstructured":"Yu G, Xu N, Huang F, Fan Z, Liu H, Shi P, Zhou H, Wang Z, Zhang Y, Liu Q. Combination of homoharringtonine with venetoclax and azacitidine excerts better treatment response in relapsed\/refractory acute myeloid leukemia. Blood. 2020;136:26\u20137.","journal-title":"Blood"},{"issue":"8","key":"1856_CR80","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00277-013-1758-5","volume":"92","author":"W Yu","year":"2013","unstructured":"Yu W, Mao L, Qian J, Qian W, Meng H, Mai W, Tong H, Tong Y, Jin J. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory\/relapsed acute myeloid leukemia: a single-center experience. Ann Hematol. 2013;92(8):1091\u2013100.","journal-title":"Ann Hematol"},{"issue":"7","key":"1856_CR81","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","volume":"14","author":"J Jin","year":"2013","unstructured":"Jin J, Wang J-X, Chen F-F, Wu D-P, Hu J, Zhou J-F, Hu J-D, Wang J-M, Li J-Y, Huang X-J. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14(7):599\u2013608.","journal-title":"Lancet Oncol"},{"key":"1856_CR82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.leukres.2016.02.012","volume":"44","author":"H-H Zhu","year":"2016","unstructured":"Zhu H-H, Jiang H, Jiang Q, Jia J-S, Qin Y-Z, Huang X-J. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8; 21). Leuk Res. 2016;44:40\u20134.","journal-title":"Leuk Res"},{"issue":"53","key":"1856_CR83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/pm.pm_67_17","volume":"14","author":"Y Li","year":"2018","unstructured":"Li Y, Zhang B, Liu M, Zhang X, Shi D, Guo L, Duan J, Zhou X, Zhu H, Zhang Q. Further study of influence of Panax notoginseng on intestinal absorption characteristics of triptolide and tripterine in rats with Tripterygium wilfordii. Pharmacogn Mag. 2018;14(53):95.","journal-title":"Pharmacogn Mag"},{"issue":"5","key":"1856_CR84","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1158\/1055-9965.EPI-13-0093","volume":"22","author":"GC Kabat","year":"2013","unstructured":"Kabat GC, Wu JW, Moore SC, Morton LM, Park Y, Hollenbeck AR, Rohan TE. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP diet and health study risk factors for chronic myeloid leukemia. Cancer Epidemiol Biomark Prev. 2013;22(5):848\u201354.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"1856_CR85","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1158\/1055-9965.EPI-09-0028","volume":"18","author":"SS Strom","year":"2009","unstructured":"Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomark Prev. 2009;18(5):1501\u20136.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1856_CR86","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","volume":"10","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, Kantarjian HM. Cortes JE Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;10:1440\u201354.","journal-title":"Mayo Clin Proc"},{"issue":"5\u20136","key":"1856_CR87","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","volume":"18","author":"LA Kujawski","year":"2007","unstructured":"Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18(5\u20136):459\u201371.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"1856_CR88","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1586\/17474086.2016.1151351","volume":"9","author":"Y Rosshandler","year":"2016","unstructured":"Rosshandler Y, Shen AQ, Cortes J, Khoury HJ. Omacetaxine mepesuccinate for chronic myeloid leukemia. Expert Rev Hematol. 2016;9(5):419\u201324.","journal-title":"Expert Rev Hematol"},{"issue":"13","key":"1856_CR89","first-page":"2573","volume":"120","author":"J Cortes","year":"2012","unstructured":"Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou A-C, Craig AR, Michallet M, Nicolini FE. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood J Am Soc Hematol. 2012;120(13):2573\u201380.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"1856_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1856_CR91","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ajh.23408","volume":"88","author":"J Cortes","year":"2013","unstructured":"Cortes J, Digumarti R, Parikh P, Wetzler M, Lipton J, Hochhaus A, Craig A, Benichou AC, Nicolini F, Kantarjian H. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013;88(5):350\u20134.","journal-title":"Am J Hematol"},{"issue":"5","key":"1856_CR92","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","volume":"36","author":"A Granatowicz","year":"2015","unstructured":"Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD, Akhtari M. An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med. 2015;36(5):197.","journal-title":"Korean J Fam Med"},{"issue":"9","key":"1856_CR93","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1080\/10428194.2017.1283030","volume":"58","author":"A Maiti","year":"2017","unstructured":"Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O\u2019Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017;58(9):2240\u20132.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1856_CR94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40487-018-0058-6","volume":"6","author":"ES Winer","year":"2018","unstructured":"Winer ES, DeAngelo DJ. A review of omacetaxine: a chronic myeloid leukemia treatment resurrected. Oncol Ther. 2018;6(1):9\u201320.","journal-title":"Oncol Ther"},{"issue":"5","key":"1856_CR95","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.leu.2400608","volume":"11","author":"G Visani","year":"1997","unstructured":"Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on \u2018in vitro\u2019growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia. 1997;11(5):624\u20138.","journal-title":"Leukemia"},{"issue":"17","key":"1856_CR96","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1182\/blood-2013-04-494773","volume":"122","author":"S Okabe","year":"2013","unstructured":"Okabe S, Tauchi T, Tanaka Y, Katagiri S, Kitahara T, Ohyashiki K. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. Blood. 2013;122(17):3086\u20138.","journal-title":"Blood"},{"issue":"8","key":"1856_CR97","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2009.52","volume":"23","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia. 2009;23(8):1446\u201354.","journal-title":"Leukemia"},{"issue":"11","key":"1856_CR98","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3109\/10428190903216838","volume":"50","author":"Y-F Li","year":"2009","unstructured":"Li Y-F, Liu X, Liu D-S, Din B-H, Zhu J-B. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy. Leuk Lymphoma. 2009;50(11):1889\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"1856_CR99","doi-asserted-by":"publisher","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","volume":"66","author":"R Chen","year":"2006","unstructured":"Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Can Res. 2006;66(22):10959\u201366.","journal-title":"Can Res"},{"issue":"1","key":"1856_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-5018-x","volume":"18","author":"T Nguyen","year":"2018","unstructured":"Nguyen T, Parker R, Zhang Y, Hawkins E, Kmieciak M, Craun W, Grant S. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. BMC Cancer. 2018;18(1):1\u201311.","journal-title":"BMC Cancer"},{"issue":"2","key":"1856_CR101","first-page":"395","volume":"26","author":"C Xie","year":"2018","unstructured":"Xie C, Tang A-P. Combined effect of Bortezomib and Homoharringtonine on K562 cells and their mechanisms. Zhongguo shi yan xue ye xue za zhi. 2018;26(2):395\u2013400.","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"1856_CR102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","author":"S O'Brien","year":"1995","unstructured":"O\u2019Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson L, Hester J, Rios M, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995. https:\/\/doi.org\/10.1182\/blood.V86.9.3322.bloodjournal8693322.","journal-title":"Blood"},{"issue":"12","key":"1856_CR103","first-page":"4149","volume":"93","author":"S O\u2019Brien","year":"1999","unstructured":"O\u2019Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E. Sequential homoharringtonine and interferon-\u03b1 in the treatment of early chronic phase chronic myelogenous leukemia. Blood J Am Soc Hematol. 1999;93(12):4149\u201353.","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"1856_CR104","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/cncr.10436","volume":"94","author":"S O'Brien","year":"2002","unstructured":"O\u2019Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth Rios M. Simultaneous homoharringtonine and interferon-\u03b1 in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002;94(7):2024\u201332.","journal-title":"Cancer"},{"issue":"20","key":"1856_CR105","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000;18(20):3513\u201321.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1856_CR106","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/cncr.20975","volume":"103","author":"D Marin","year":"2005","unstructured":"Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF. Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer. 2005;103(9):1850\u20135.","journal-title":"Cancer"},{"issue":"2","key":"1856_CR107","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/cncr.22398","volume":"109","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Garcia-Manero G, O\u2019Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S. Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007;109(2):248\u201355.","journal-title":"Cancer"},{"issue":"5","key":"1856_CR108","first-page":"888","volume":"98","author":"S O'Brien","year":"2003","unstructured":"O\u2019Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in early chronic phase. Cancer Interdiscip Int J Am Cancer Soc. 2003;98(5):888\u201393.","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"issue":"1","key":"1856_CR109","first-page":"156","volume":"117","author":"R Chen","year":"2011","unstructured":"Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood J Am Soc Hematol. 2011;117(1):156\u201364.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"1856_CR110","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1535-7163.MCT-09-0468","volume":"9","author":"Y Jin","year":"2010","unstructured":"Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther. 2010;9(1):211\u201323.","journal-title":"Mol Cancer Ther"},{"issue":"248","key":"1856_CR111","doi-asserted-by":"publisher","first-page":"369","DOI":"10.31729\/jnma.7359","volume":"60","author":"SK Sah","year":"2022","unstructured":"Sah SK, Shah S, Tiwari SB, Poudel BS, Singh B, Sharma P, Acharya SS, Murarka H, Thapaliya S, Shrestha A. Essential thrombocythemia among patients with myeloproliferative neoplasms in haematology unit of a Tertiary Care Centre: a descriptive cross-sectional study. JNMA J Nepal Med Assoc. 2022;60(248):369\u201373. https:\/\/doi.org\/10.31729\/jnma.7359.","journal-title":"JNMA J Nepal Med Assoc"},{"issue":"5","key":"1856_CR112","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s10147-012-0453-1","volume":"18","author":"Y Li","year":"2013","unstructured":"Li Y, Zhu J, Ding B. Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-\u03b1 therapy. Int J Clin Oncol. 2013;18(5):922\u20136.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"1856_CR113","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B, Lei Y, Du S, Vuppalapati A, Luu HH, Haydon RC, He TC, Ren G. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77\u2013106. https:\/\/doi.org\/10.1016\/j.gendis.2018.05.001.","journal-title":"Genes Dis"},{"issue":"20","key":"1856_CR114","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.3390\/nu15204357","volume":"15","author":"AG Urz\u00ec","year":"2023","unstructured":"Urz\u00ec AG, Tropea E, Gattuso G, Spoto G, Marsala G, Calina D, Libra M, Falzone L. Ketogenic diet and breast cancer: recent findings and therapeutic approaches. Nutrients. 2023;15(20):4357.","journal-title":"Nutrients"},{"issue":"5","key":"1856_CR115","first-page":"1043","volume":"9","author":"M Yakhni","year":"2019","unstructured":"Yakhni M, Briat A, El Guerrab A, Furtado L, Kwiatkowski F, Miot-Noirault E, Cachin F, Penault-Llorca F, Radosevic-Robin N. Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance. Am J Cancer Res. 2019;9(5):1043.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"1856_CR116","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00277-018-3247-3","volume":"97","author":"P Chen","year":"2018","unstructured":"Chen P, Wen X, Wang B, Hou D, Zou H, Yuan Q, Yang H, Xie J, Huang H. PI3K\/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft. Ann Hematol. 2018;97(5):865\u201375.","journal-title":"Ann Hematol"},{"issue":"1","key":"1856_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep08477","volume":"5","author":"W Cao","year":"2015","unstructured":"Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6\/JAK1\/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 2015;5(1):1\u201317.","journal-title":"Sci Rep"},{"issue":"1","key":"1856_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-26454-w","volume":"8","author":"T-Y Weng","year":"2018","unstructured":"Weng T-Y, Wu HF, Li C-Y, Hung Y-H, Chang Y-W, Chen Y-L, Hsu H-P, Chen Y-H, Wang C-Y, Chang J-Y. Homoharringtonine induced immune alteration for an efficient anti-tumor response in mouse models of non-small cell lung adenocarcinoma expressing Kras mutation. Sci Rep. 2018;8(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"2","key":"1856_CR119","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF00685333","volume":"33","author":"LJ Wilkoff","year":"1993","unstructured":"Wilkoff LJ, Dulmadge EA, Vasanthakumar G, Donahue JP. Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine. Cancer Chemother Pharmacol. 1993;33(2):149\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1856_CR120","doi-asserted-by":"publisher","first-page":"592071","DOI":"10.3389\/fphar.2021.592071","volume":"12","author":"H Wang","year":"2021","unstructured":"Wang H, Wang R, Huang D, Li S, Gao B, Kang Z, Tang B, Xie J, Yan F, Liang R. Homoharringtonine exerts anti-tumor effects in hepatocellular carcinoma through activation of the hippo pathway. Front Pharmacol. 2021;12:592071.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1856_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-02902-2","volume":"11","author":"M Zhu","year":"2020","unstructured":"Zhu M, Gong Z, Wu Q, Su Q, Yang T, Yu R, Xu R, Zhang Y. Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated \u03b2-catenin loss in hepatocellular carcinoma. Cell Death Dis. 2020;11(8):1\u201313.","journal-title":"Cell Death Dis"},{"key":"1856_CR122","doi-asserted-by":"publisher","first-page":"114731","DOI":"10.1016\/j.ejmech.2022.114731","volume":"244","author":"Y Yang","year":"2022","unstructured":"Yang Y, Yu Q, Hu L, Dai B, Qi R, Chang Y, Zhang Q, Zhang Z, Li Y, Zhang X. Enantioselective semisynthesis of novel cephalotaxine esters with potent antineoplastic activities against leukemia. Eur J Med Chem. 2022;244:114731.","journal-title":"Eur J Med Chem"},{"key":"1856_CR123","doi-asserted-by":"publisher","first-page":"110960","DOI":"10.1016\/j.fct.2019.110960","volume":"136","author":"X Shi","year":"2020","unstructured":"Shi X, Zhu M, Gong Z, Yang T, Yu R, Wang J, Zhang Y. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K\/AKT and MAPK\/EKR1\/2 signaling pathways. Food Chem Toxicol. 2020;136:110960.","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"1856_CR124","doi-asserted-by":"publisher","first-page":"12940","DOI":"10.1080\/21655979.2021.2012626","volume":"12","author":"M Qu","year":"2021","unstructured":"Qu M, Li J, Yuan L. Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation. Bioengineered. 2021;12(2):12940\u201353.","journal-title":"Bioengineered"},{"issue":"2","key":"1856_CR125","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/bkcs.11662","volume":"40","author":"M Park","year":"2019","unstructured":"Park M, Kwon HJ, Kim SH. Homoharringtonine induces apoptosis in human colorectal carcinoma HCT116 cells via downregulation of Wnt\/\u03b2-catenin signaling cascade. Bull Korean Chem Soc. 2019;40(2):196\u20139.","journal-title":"Bull Korean Chem Soc"},{"issue":"6","key":"1856_CR126","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10495-013-0823-9","volume":"18","author":"L Beranova","year":"2013","unstructured":"Beranova L, Pombinho AR, Spegarova J, Koc M, Klanova M, Molinsky J, Klener P, Bartunek P, Andera L. The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms. Apoptosis. 2013;18(6):739\u201350.","journal-title":"Apoptosis"},{"key":"1856_CR127","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.eclinm.2023.102193","volume":"64","author":"D Wu","year":"2023","unstructured":"Wu D, Jin Y, Xing Y, Abate MD, Abbasian M, Abbasi-Kangevari M, Abbasi-Kangevari Z, Abd-Allah F, Abdelmasseh M, Abdollahifar MA, Abdulah DM. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019. EClinicalMedicine. 2023;64:102193. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102193.","journal-title":"EClinicalMedicine"},{"key":"1856_CR128","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02694-0","author":"R Kumari","year":"2023","unstructured":"Kumari R, Negi M, Thakur P, Mahajan H, Raina K, Sharma R, Singh R, Anand V, Ming LC, Goh KW, Calina D, Sharifi-Rad J, Chaudhary A. Saussurea costus (Falc.) Lipsch.: a comprehensive review of its pharmacology, phytochemicals, ethnobotanical uses, and therapeutic potential. Naunyn Schmiedebergs Arch Pharmacol. 2023. https:\/\/doi.org\/10.1007\/s00210-023-02694-0.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"1856_CR129","first-page":"143","volume":"15","author":"G Yuan","year":"2006","unstructured":"Yuan G, Wahlqvist ML, He G, Yang M, Li D. Natural products and anti-inflammatory activity. Asia Pac J Clin Nutr. 2006;15(2):143\u201352.","journal-title":"Asia Pac J Clin Nutr"},{"key":"1856_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-308X(01)50032-9","volume-title":"Antiparasitic properties of medicinal plants and other naturally occurring products","author":"S Tagboto","year":"2001","unstructured":"Tagboto S, Townson S. Antiparasitic properties of medicinal plants and other naturally occurring products. Amsterdam: Elsevier; 2001."},{"issue":"14","key":"1856_CR131","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.phymed.2016.10.008","volume":"23","author":"S Krstin","year":"2016","unstructured":"Krstin S, Mohamed T, Wang X, Wink M. How do the alkaloids emetine and homoharringtonine kill trypanosomes? An insight into their molecular modes of action. Phytomedicine. 2016;23(14):1771\u20137.","journal-title":"Phytomedicine"},{"issue":"Pt a","key":"1856_CR132","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"R Anand","year":"2014","unstructured":"Anand R, Gill K, Mahdi A. Therapeutics of Alzheimer\u2019s disease: past, present and future. Neuropharmacology. 2014;76(Pt a):27\u201350.","journal-title":"Neuropharmacology"},{"issue":"9","key":"1856_CR133","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s11064-012-0799-9","volume":"37","author":"MM Essa","year":"2012","unstructured":"Essa MM, Vijayan RK, Castellano-Gonzalez G, Memon MA, Braidy N, Guillemin GJ. Neuroprotective effect of natural products against Alzheimer\u2019s disease. Neurochem Res. 2012;37(9):1829\u201342.","journal-title":"Neurochem Res"},{"key":"1856_CR134","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fphar.2018.00548","volume":"9","author":"B Shal","year":"2018","unstructured":"Shal B, Ding W, Ali H, Kim YS, Khan S. Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer\u2019s disease. Front Pharmacol. 2018;9:548.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1856_CR135","first-page":"24","volume":"4","author":"IO Korolev","year":"2014","unstructured":"Korolev IO. Alzheimer\u2019s disease: a clinical and basic science review. Med Stud Res J. 2014;4(1):24\u201333.","journal-title":"Med Stud Res J"},{"issue":"1","key":"1856_CR136","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1568014053005372","volume":"4","author":"E Nettis","year":"2005","unstructured":"Nettis E, Colanardi M, Ferrannini A, Tursi A. Antihistamines as important tools for regulating inflammation. Curr Med Chem Anti-Inflamm Anti-Allergy Agents. 2005;4(1):81\u20139.","journal-title":"Curr Med Chem Anti-Inflamm Anti-Allergy Agents"},{"key":"1856_CR137","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1590\/S0100-879X2007000100014","volume":"40","author":"F Brito","year":"2007","unstructured":"Brito F, Lima L, Ramos M, Nakamura M, Cavalher-Machado S, Siani A, Henriques M, Sampaio A. Pharmacological study of anti-allergic activity of Syzygium cumini (L.) Skeels. Braz J Med Biol Res. 2007;40:105\u201315.","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"1856_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-3-254","volume":"3","author":"BA Bakhotmah","year":"2010","unstructured":"Bakhotmah BA, Alzahrani HA. Self-reported use of complementary and alternative medicine (CAM) products in topical treatment of diabetic foot disorders by diabetic patients in Jeddah, Western Saudi Arabia. BMC Res Notes. 2010;3(1):1\u20138.","journal-title":"BMC Res Notes"},{"issue":"7","key":"1856_CR139","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1359-6446(00)01511-7","volume":"5","author":"A Harvey","year":"2000","unstructured":"Harvey A. Strategies for discovering drugs from previously unexplored natural products. Drug Discov Today. 2000;5(7):294\u2013300.","journal-title":"Drug Discov Today"},{"key":"1856_CR140","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/187221312800166886","volume":"6","author":"Y Bellik","year":"2012","unstructured":"Bellik Y, Hammoudi S, Abdellah F, Iguer-Ouada M, Boukraa L. Phytochemicals to prevent inflammation and allergy. Recent Pat Inflamm Allergy Drug Discov. 2012;6:147\u201358.","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"1856_CR141","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3389\/fphar.2020.01032","volume":"11","author":"M Kim","year":"2020","unstructured":"Kim M, Jo H, Kwon Y, Kim Y, Jung HS, Jeoung D. Homoharringtonine inhibits allergic inflammations by regulating NF-\u03baB-miR-183-5p-BTG1 axis. Front Pharmacol. 2020;11:1032.","journal-title":"Front Pharmacol"},{"issue":"10397","key":"1856_CR142","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, Dalton BE, Duprey J, Cruz JA, Hagins H, Lindstedt PA. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334. https:\/\/doi.org\/10.1016\/s0140-6736(23)01301-6.","journal-title":"Lancet"},{"issue":"6","key":"1856_CR143","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00395-011-0216-6","volume":"106","author":"Y Ye","year":"2011","unstructured":"Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia\u2013reperfusion injury. Basic Res Cardiol. 2011;106(6):925\u201352.","journal-title":"Basic Res Cardiol"},{"key":"1856_CR144","doi-asserted-by":"publisher","unstructured":"Severino P, D'Amato A, Netti L, et al. Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow. J Diabetes Res. 2019:9489826.https:\/\/doi.org\/10.1155\/2019\/9489826. Accessed 4 Apr 2019.","DOI":"10.1155\/2019\/9489826"},{"key":"1856_CR145","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.yjmcc.2017.05.010","volume":"108","author":"S Zhao","year":"2017","unstructured":"Zhao S, Xia Y, Zhang F, Xiong Z, Li Y, Yan W, Chen X, Wang W, Wang H, Gao E. Nucleostemin dysregulation contributes to ischemic vulnerability of diabetic hearts: role of ribosomal biogenesis. J Mol Cell Cardiol. 2017;108:106\u201313.","journal-title":"J Mol Cell Cardiol"},{"issue":"3 Pt B","key":"1856_CR146","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3851\/IMP1499","volume":"15","author":"SA Locarnini","year":"2010","unstructured":"Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antiviral Ther. 2010;15(3 Pt B):451\u201361.","journal-title":"Antiviral Ther"},{"issue":"3","key":"1856_CR147","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1469-0691.2010.03441.x","volume":"17","author":"L Christou","year":"2011","unstructured":"Christou L. The global burden of bacterial and viral zoonotic infections. Clin Microbiol Infect. 2011;17(3):326\u201330.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1856_CR148","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12275-019-8514-z","volume":"57","author":"J-E Kim","year":"2019","unstructured":"Kim J-E, Song Y-J. Anti-varicella-zoster virus activity of cephalotaxine esters in vitro. J Microbiol. 2019;57(1):74\u20139.","journal-title":"J Microbiol"},{"issue":"06","key":"1856_CR149","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1055\/s-2007-967184","volume":"73","author":"MR Romero","year":"2007","unstructured":"Romero MR, Serrano MA, Efferth T, Alvarez M, Marin JJ. Effect of cantharidin, cephalotaxine and homoharringtonine on\u201d in vitro\u201d models of Hepatitis B Virus (HBV) and Bovine Viral Diarrhoea Virus (BVDV) replication. Planta Med. 2007;73(06):552\u20138.","journal-title":"Planta Med"},{"issue":"10","key":"1856_CR150","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/v11100964","volume":"11","author":"PI Andersen","year":"2019","unstructured":"Andersen PI, Krpina K, Ianevski A, Shtaida N, Jo E, Yang J, Koit S, Tenson T, Hukkanen V, Anthonsen MW. Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine. Viruses. 2019;11(10):964.","journal-title":"Viruses"},{"issue":"1","key":"1856_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-020-01342-w","volume":"17","author":"C-C Li","year":"2020","unstructured":"Li C-C, Wang X-J. Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro. Virol J. 2020;17(1):1\u201311.","journal-title":"Virol J"},{"issue":"3","key":"1856_CR152","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12250-020-00316-0","volume":"36","author":"J-W Zhang","year":"2021","unstructured":"Zhang J-W, Wang H, Liu J, Ma L, Hua R-H, Bu Z-G. Generation of a stable GFP-reporter Zika virus system for high-throughput screening of Zika virus inhibitors. Virol Sin. 2021;36(3):476\u201389.","journal-title":"Virol Sin"},{"issue":"1","key":"1856_CR153","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","volume":"19","author":"F Alvandi","year":"2014","unstructured":"Alvandi F, Kwitkowski VE, Ko C-W, Rothmann MD, Ricci S, Saber H, Ghosh D, Brown J, Pfeiler E, Chikhale E. US Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist. 2014;19(1):94\u20139.","journal-title":"Oncologist"},{"key":"1856_CR154","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-021-2093-2","author":"H Ma","year":"2022","unstructured":"Ma H, Wen H, Qin Y, Wu S, Zhang G, Wu C-I, Cai Q. Homo-harringtonine, highly effective against coronaviruses, is safe in treating COVID-19 by nebulization. Sci China Life Sci. 2022. https:\/\/doi.org\/10.1007\/s11427-021-2093-2.","journal-title":"Sci China Life Sci"},{"key":"1856_CR155","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"K Choy","year":"2020","unstructured":"Choy K, Wong AY-L, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP-H, Huang X, Peiris M, Yen HL. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.","journal-title":"Antiviral Res"},{"issue":"2","key":"1856_CR156","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/ptr.6873","volume":"35","author":"M Boozari","year":"2021","unstructured":"Boozari M, Hosseinzadeh H. Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies. Phytother Res. 2021;35(2):864\u201376.","journal-title":"Phytother Res"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-01856-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-024-01856-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-01856-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T01:16:49Z","timestamp":1731892609000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-024-01856-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1186\/s40001-024-01856-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"13 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}